[CLINICAL AND X-RAY CHANGES IN PATIENTS WITH NEW-ONSET MULTIDRUG-RESISTANT MYCOBACTERIUM PULMONARY TUBERCULOSIS IN THE EARLY USE OF A RESERVE CHEMOTHERAPY REGIMEN ACCORDING TO THE TB-BIOCHIP TEST SYSTEM DATA].
Clinical and X-ray changes were comparatively studied in new-onset tuberculosis patients excreting susceptible Mycobacterium tuberculosis (MBT) and mutidrug resistant (MDR) MBT. Eighty tuberculosis patients who had not received antituberculous drugs were followed up. Before chemotherapy, sputum was tested in all cases, by using the TB-biochip system, to determine drug susceptibility of MBT. According to the results of microchip diagnosis, the patients were divided into 2 groups: 1) patients with primary MRD MBT (a study group) and 2) those with MBT susceptible to all drugs (a control group). A chemotherapy regimen involving a combination of reserve drugs was given in Group 1 while Group 2 received standard regimen 1 that comprised basic series drugs. The timely use of the adequate therapy regimen in patients with MDR tuberculosis could achieve a high efficiency of therapy in a short period in terms of the bacterial excretion rate in 97.5 and 100% and in the terms of the decay cavity healing rate in 92.5 and 97.5% in Groups 1 and 2, respectively At the same time after termination of a 6-month course of therapy, both groups showed a preponderance of minimum residual changes as scars (37.5 and 45.0%) and fibrous foci (52.5 and 50.0%).